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Background: Assent is an important ethical and legal requirement of paediatric research. Unfortunately, there are
significant differences between the guidelines on the details of assent.
Discussion: What often remains unclear is the scope of the assent, the procedure for acquiring it, and the way in
which children’s capacity to assent is determined. There is a general growing tendency that suggests that the
process of assent should be personalised, that is, tailored to a particular child. This article supports the idea of
personalisation. However, we also propose placing limits on personalisation by introducing a suggested
requirement of assent starting at a school-age threshold. In some situations RECs/IRBs and researchers could reduce
the suggested threshold.
Summary: A recommended age threshold is likely to serve the interests of children better than ambiguous and
flexible criteria for personalised age determination.
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One of the most important ethical and legal principles that
results from respect for the autonomy of participants in
biomedical research is the voluntary nature of participa-
tion. In order to secure this, many countries have adopted
a policy of providing research participants with basic writ-
ten information together with a suggestion for researchers
to discuss any extra details that the potential participant
may wish to learn more about [1]. For people taking part
in research who do not have full capacity, informed con-
sent must be acquired from a legal guardian or a represen-
tative. Often the assent of a research participant without
full capacity is also needed. Most international guidelines
on the ethics of human research stress that the principle
of assent must also be applied in paediatric research [2-6].
However, sometimes the concept of assent is criticised as
a contentious term which, by replacing children’s consent,
weakens their position in the decision-making process
[7]. Moreover, what often remains unclear is the scope
of this assent, the procedure for acquiring it, and the* Correspondence: m.waligora@uj.edu.pl
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For nearly 30 years, commentators have been discussing
a number of different aspects of assent and its personal-
isation. For example, Priscilla Alderson and Jonathan
Montgomery recommended that all discussions with
children regarding participation in research should start
from the presumption of children’s competence, rather
than the assumption that the child is incompetent [8].
Phaik Yeong Cheah and Michael Parker argue that, es-
pecially in some low-income settings, children may be
better informed and educated than their parents, and
thus in some cases should be able not to assent but to
consent for themselves [9]. Other authors are in favour
of an increase in the role of parents in taking decisions
for the children to participate in the research. Accord-
ing to Tessa John et al., parents should interpret their
child’s behaviour and statements, assessing the signifi-
cance of their dissent and assent [10]. Barbara E. Gibson
et al. propose implementing a “family decision-making”
model [11]. They argue that joint family consent should
replace separate parental consent and child’s assent. A
similar opinion is held by Steven Joffe, who at the same
time recommends rejecting the term “assent” as not en-
tirely clear, in favour of “affirmative agreement” [12].
Paul Baines proposes abandoning the requirement toal Ltd. This is an Open Access article distributed under the terms of the Creative
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gues, we should not ask them for assent. Yet if they are
competent, they should be able to express not assent, but
consent [13]. Noor A. A. Giesbertz et al. argue the case for
the introduction of personalised assent, saying that the
value of assent is not in assuring the safety of participa-
tion, but in engagement grounds. Assent helps to develop
a child’s autonomy, plays the role of educational tool, and
supports communication between the researcher and the
child. The content and the process of decision making in
assent should thus be adjusted to the individual child
[14-16]. Other authors claim that, in the process of the
parental and child’s decision making, advanced methods
could help with transmitting knowledge of the research,
making it easy to understand for the parents as well as the
children [17].
We believe that assent is an important part of the
current paradigm of free and voluntary participation in
biomedical research, and also support the view that
assent plays an important role in the process of the de-
velopment of a child’s autonomy. In general, we are
sympathetic to many aspects of the idea of personalised
assent. In this article, however, we will focus solely on
the problem of personalised determination of age of
assent. Our proposal is that personalisation should be
limited by a suggested requirement of assent starting at
a certain age threshold.
Discussion
Personalisation of the age of assent
According to some of the international instruments regu-
lating human research, the power of influence of a child’s
assent should increase with age [4,5]. Some professional
and national recommendations, meanwhile, specify an un-
ambiguous age limit for children that marks the need for
acquisition of assent. The UK Royal College of Paediatrics
defines this as “school age” [18]. In the United States, the
National Commission for the Protection of Human Sub-
jects of Biomedical and Behavioral Research sets this point
at a child’s seventh birthday [19]. The American Academy
of Pediatrics also supported this age threshold until 2010
[20], but now applies less strict requirements [21].
There is a general growing tendency in favour of per-
sonalisation of the process of assessment of the age of
assent, i.e. suggesting that it should be tailored to a par-
ticular child. Here commentators use different argu-
ments. Firstly, large developmental differences between
children of the same age and differences in experience
influence a child’s ability to understand essential informa-
tion, such as the purpose, risk and benefit of research. In
particular, children undergoing long-term medical treat-
ment demonstrate surprising competences concerning
their own medical situation [22]. Secondly, especially with
smaller children, their verbal and non-verbal messagesdemand advanced interpretation and assessment, thus
making it difficult for a research team to assess the ma-
turity and level of understanding of a child. Most au-
thors agree that in this case an important role should be
played by the parents, who are the best at interpreting
the behaviours of their own children. Parents could also
be asked whether the child is old and competent enough
to assent [10,11,23].
Unfortunately, the whole interesting idea of personal-
isation of age of assent makes the entire process difficult
to enforce: it implies sophisticated and time-consuming
methods of interpretation of children’s behaviours with-
out clear instruments of assessment and, if not made
obligatory, is likely to be avoided when possible. In
addition, a joint decision taken by the family and child
assumes a certain model of family relations. This model
is characterised by the mutual understanding of the family
members, parental protectiveness, care and attention in
supporting the children’s aspirations. The researchers
described in this model are characterised by high moral
integrity. Personalised assent falls short entirely in per-
haps rare cases when parents do not have the necessary
skills for communicating properly with their children.
As a result, parents do not know accurately enough
what the children’s needs and preferences are. In some
cases parents may also simply attach less importance to
acting for their children’s good, and as a consequence,
may not act in their child’s best interest. In such cir-
cumstances it is likely that the family will assign little
significance to the assent of the child. It will be a similar
story when the researcher is above all interested in the
speed of recruitment. With some clinical trials, assent
must be acquired within a matter of days or even hours,
and there is no time for subtle interpretations and recon-
tact [24]. A comprehensive proposal regarding acquisition
of assent cannot exclude the abovementioned situations
and institutional problems, and needs further discussion.
Otherwise, there is a real risk that extensive, sometimes
unclear and incompatible ethical recommendations would
be applied very inconsistently. This is true of the Polish
part of the large multicentre GABRIEL study, where
assent was not sought.
A case from the Gabriel project
The GABRIEL project was the largest study to date on
the genetics of asthma [25]. The research included
10,365 people diagnosed with asthma and 16,110 un-
affected people. Part of the GABRIEL project study took
place in Poland. This section of the study was conducted
in schools located in rural areas and small towns. In the
first phase of the study, questionnaires on asthmatic com-
plaints were collected from parents of affected children,
who were sent a letter with information on the study and
a consent form regarding the realisation of the second
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40,000) gave their consent to their child’s participation
in the second phase of the study. This comprised both
obtaining further information from the parents and a
qualified nurse taking a blood sample and nasal swab
and performing a prick skin test on school grounds.
These tests were conducted on a random selection of
children from the group of 9,677 [26,27].
After the second phase, a further visit took place in
schools, during which additional information was ac-
quired, including asking the children for their opinions on
participation in the main genetic study [27]. Distribution
of the “participation questionnaire” began at the point
when around half of these second school visits were
complete. A total of 706 children aged 6–14 filled in
the additional form. This supplementary study gives us
detailed information on the participation of children in
the decision-making process in relation to their partici-
pation in the genetic research.
The results of the study by Sylvia van der Pal et al. are
rather surprising. The study protocol on genetic research
did not foresee any form of joint decision by children and
parents on whether they would take part in the genetic re-
search: “The children were informed about the study by
the research team but were not officially asked for their
assent as part of the official study protocol” [27]. Accord-
ing to Polish law it is possible to obtain written consent
for participation in biomedical research of minors aged 16
and older. It is also necessary, in addition to the consent
of a legal representative, to acquire written consent from
minors under 16, provided that they are able to give an in-
formed opinion regarding participation: “The participation
of juveniles in medical experimentation is permitted only
provided that written informed consent of a legal repre-
sentative is obtained. When a juvenile is aged 16 years or
younger and is able to give a duly informed opinion about
his/her participation in the experiment, his/her written
consent is also required.” [28].
Van der Pal et al.’s article lacks any information as to
whether any criteria of capability of children were ap-
plied, or whether it was decided that even the oldest of
the children participating in the research did not pos-
sess the capability to give an informed opinion on their
participation.
Although Polish law does in fact not contain such a
requirement, obtaining assent and determining dissent
constitute a standard according to many international
guidelines. However, most recommendations are vague,
and leave the evaluation of a child’s capability up to the
researcher, Regional Ethics Committees (RECs), or Insti-
tutional Review Boards (IRBs). There is also a lack of
clear procedures determining children’s capability. Some
commentators are in favour of an increase in the influ-
ence of parents on the procedure of assent or replacingthe separate consent of parents and assent of children
with a joint decision procedure [10,11]. We should there-
fore examine the information provided by children as to
their actual participation in the decision-making process.
One to four months after the genetic research, just 54%
of children claimed that their parents had asked their
opinion on participation in the studies. Some 42% stated
that “nobody asked my opinion about participating in
the study”. However, 39% thought that “parents and
children should both be asked for permission”, and 33%
that “children my age should always give permission”.
What can be learned from the Gabriel case?
As the Polish part of the GABRIEL case, followed by the
study by van der Pal et al., gives limited data, we would
like to avoid overgeneralisation regarding the actual
process of obtaining assent in paediatric research. How-
ever, this case indicates a problem which should become
the subject of further investigation. It also allows one to
propose some hypotheses for further studies. The lack
of assent in the GABRIEL case might have been caused
by various factors. The question is why investigators did
not design the study to meet international ethical re-
quirements. Most international guidelines, such as the
Declaration of Helsinki and the Oviedo Convention, are
well known in Poland. Moreover, Polish law assumes
the necessity of consent being obtained from children
under 16 in the case of clinical trials, yet the genetic re-
search in question did not put this possibility to use. It
is likely that the failure to instigate the procedure of
assent was caused by some social and structural factors.
Despite the fact that Poland is a member of the European
Union and has implemented the European Commission
Directive concerning Good Clinical Practice, it still faces
many problems characteristic of a transition society. These
aspects have been analysed elsewhere [29]. However, we
suspect that this may be a more general phenomenon. If
researchers’ priority is a high level of efficiency, then many
procedures and ethical suggestions are considered as an
additional administrative burden. When a recommenda-
tion is ambiguous and not enforced by law, a requirement
unclear and vague, then it is also not obvious how it
should be applied in practice. Subtle ethical distinctions
can then become much less applicable in practice. Since
the local legislation did not foresee the need to gain assent,
and international guidelines in this respect remain vague,
this genetic research also did not contain such a proced-
ure. Our hypothesis is that clear information concerning
the minimum age at which it is required to obtain assent
will make it more likely that children are asked for assent.
The age threshold complements the concept of person-
alisation and gives a clear suggestion for RECs as well as
researchers. However, we realise that a fundamental diffi-
culty here is in designating such an age. Let us therefore
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concerning their understanding of medical procedures.
Capacities of children according to studies
Research on the capacity of children in the context of
biomedical studies is varied in terms of methodology and
the composition of the groups studied (Table 1). Indeed,
some studies do not even distinguish between the terms
“assent” and “consent”. It is therefore difficult to systemat-
ically compile and compare the results of these studies
[30]. Nonetheless, the conclusions presented in all these
reports give useful information about children’s capacities
of participation in the decision-making process.
The majority of studies assessing children’s compe-
tence in understanding information related to research
focus on children, adolescents and young adults be-
tween around 7 and 20 years old. Most of these studies
support the hypothesis that children are more capable
than usually thought. Lois A. Weithorn and Susan B.
Campbell examined the competency to make medical
decisions of 96 subjects aged 9 to 21. They concluded
that 9-year-old children are able to “participate mean-
ingfully” in the healthcare decision-making process [31].
Based on the similar results of a study undertaken with
six children aged 7 to 12 years old, Sue Miller advocates
appropriate assessment of children’s awareness and ap-
peals against underestimating their abilities to assent
[32]. The research conducted by Gail Geller et al. alsoTable 1 Capacities of children according to studies
Author Year Number of
subjects




1982 96 9-21 “What happens if a
taking insulin and m
injection?”
Abramovitch R et al. 1991 163 5-21 “Should you be in a s
didn’t like it and yo
did?”
Susman EJ et al. 1992 44 7-20 “What are the side
taking your treat
Ondrusek N et al. 1998 18 5-18 “What good things m
to other people beca
in this study
Miller S 2000 6 7-12 “The children were […
talk about their likes a








Burke TM et al. 2005 251 6-13 “Can you think of any
about being in theprovides data supporting the statement that children as
young as 10 want to participate in the consent process.
This willingness is in many cases also supported by
parents, who often wish to involve their children in the
entire process of consent/assent [33].
Several studies have also assessed younger children’s
capacity for comprehension of treatment and research.
One of these questioned young children’s capacity to
participate in a medical decision-making process. This
was a pilot study conducted by Nancy Ondrusek et al.
performed with the participation of 18 healthy children,
the focus of which was on an assent process for non-
therapeutic medical research [34]. According to the au-
thors of this study, most children younger than 9 years
old are not able to participate in the decision-making
process in a substantial way. Other research offers a posi-
tive assessment of young children’s capacity for under-
standing the essence of medical procedures and associated
important information.
Rona Abramovitch et al. examined the children’s
decision-making process regarding participation in psy-
chological research in a series of studies with 163 people
aged 5–12 [35]. In one of these studies the subjects in-
cluded 21 children of 5 and 6 years old. Some 62% of
these children gave adequate answers to the researcher’s
questions, and most of them gave a reasonable account
of what would happen in the study after it had been de-





“Children as young as 9 appear able to participate
meaningfully in personal health-care decision making”.
tudy if you
ur mother
“If the instructions are given clearly and the study is not
excessively complex, most children as young as 5 are
capable of understanding what they will be doing and




“Although we found no age differences, developmental
differences do exist among children, adolescents, and
adults […]. Adolescents and young adults were no better




“In subjects younger than 9 years of age, understanding of




Researchers should not “underestimate the awareness and
maturity that some children possess when addressing
issues of concern to themselves”.
garding
sed.
“Most children wanted or expected some degree of




“By creating age appropriate modules of information,
children as young as six years can understand potentially
difficult and complex concepts […] associated with
participation in biomedical research”.
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able to understand why the study was being conducted.
The authors concluded that in the case of clear instruc-
tions most children aged 5 have the capacity to give
assent or dissent to participation in psychological or
medical research. Tara M. Burke et al. evaluated under-
standing of the risk and benefits associated with bio-
medical research among 251 children aged 6–15 and
237 adults [36]. For many answers, researchers found
significant differences between age groups. The youngest
group consisted of children aged 6–9 (“the youngest”).
Only 24% of them defined the term “research” appropri-
ately (72% of adults were able to define it), while 73%
understood the purpose of the study. Some 62% of them
were able to provide a reasonable response to the question
“What will the doctors and nurses do if I decide to be in
the study?”, while 56% were able to reasonably describe
the benefits (“any good things about being in the study”)
and 64% the risks (“any bad things about being in the
study”) of the study. The authors concluded that the re-
sults supported their hypothesis regarding understanding
complex concepts such as the risk and benefits of biomed-
ical research among children aged 6–9.
Fixing the threshold does not imply that content of
information provided while seeking assent should not
be influenced by considerations of development. For ex-
ample, Elisabeth J. Susman et al. examined competences
for reasonable assent and consent for participation in
biomedical research among 44 children and young adults
(aged 7–20) [37]. The authors concluded that the study
subjects more clearly understood concrete information
and were less knowledgeable about elements of informed
consent that assessed abstract information. It would be
natural to use this kind of information in selecting opti-
mal information to be communicated during the assent
procedure.
In addition to differences in terms of methodology,
there are also other factors which make a clear compari-
son between all the cited studies difficult. For instance,
the standardised tests set by developmental psycholo-
gists may not allow children to understand some ques-
tions, while more open questions followed by discussion
with young participants may more fully explore children’s
capacities. Some studies implied a lack of understanding
among children based on their incapacity. Nevertheless,
the problem may lie in inadequate explanations. Another
important factor is the difference between the capacities
of healthy and young children with long-term illnesses.
This may help to explain the results of Ondrusek et al.’s
pilot study based on research with healthy children.
Personalised assent: a proposed modification
The studies on children’s capacity to understand informa-
tion concerning research carried out to date have notgiven clear pointers regarding the age from which assent
must absolutely be obtained in paediatric research. None-
theless, most of them point to the rather considerable cap-
acities of 5–7 year-old children. Based on this limited data
we could propose an age threshold: children aged 5–7
should be asked to assent to their participation in biomed-
ical research. We call this threshold a school-age thresh-
old. We suggest that in some situations, where necessary,
RECs/IRBs could reduce the suggested threshold. Should
new data be obtained regarding capacities of children
younger than 5 years old, this suggested threshold could
also be reduced.
Commentators favouring a more individualised ap-
proach might object to our proposal and argue that the
idea of personalised assent fulfils the recommendation
concerning each child being treated in a way that is
adapted to individual expectations and level of develop-
ment. The example of the part of the GABRIEL project
research carried out in Poland, however, illustrates that
suggestions regarding children’s participation in the de-
cision process could be insufficient. The key for both
RECs/IRBs and researchers is clear and unambiguous
solutions. In the United States and United Kingdom,
some institutions suggest that assent must be obtained
from school age. Designating such a limit brings with it
the threat of over- or underestimating children’s cap-
acity to make important decisions [12,38-40]. We there-
fore propose connecting the suggested age threshold
with personalisation by empowering RECs/IRBs and re-
searchers to reduce that minimum age in certain situa-
tions. The complexity of the study, the child’s previous
experience and similar factors impact a child’s ability to
assent. RECs/IRBs could change the suggested thresh-
old in these situations. Researchers should be encour-
aged to discuss the details of children’s participation
with them and personalise the way in which all provided
information is communicated. In our view this modifi-
cation of personalisation by introducing a suggested re-
quirement of assent starting at a certain age threshold is
more adequate.
There are several arguments in favour of our proposal
of modification of personalisation of assent. The most
important is that of clarity. If a requirement is not
enforced by law, then its impact depends greatly, among
other factors, on the clarity of guidelines. An age threshold
with the possibility of personalisation of assent is more
likely to serve the interest of children better than com-
pletely flexible criteria of personalisation. The more
vague a guideline, the more likely it will not be followed
by RECs/IRBs and researchers. Moreover, future possible
audits aimed at identification of assent would be based on
a clear requirement.
The second argument is that of comprehensiveness of
social rules. In similar situations social rules based on
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paediatric research too there is no sufficient reason to
object to this. We accept age limits in many other situa-
tions in society, although there is always the risk of arbi-
trariness. Children attend pre-school from a certain age,
for example. Furthermore, many countries have an edu-
cation requirement categorically connected to the age
criterion, while the right to acquire a driving licence at a
certain age is similarly arbitrary. The degree of maturity
and responsibility of people aged 18 or 21 also varies
considerably. Nevertheless, such legally designated age
limits are accepted. The third argument is that of mini-
mising subjective assessment. Deciding on a suggested
age threshold once may be less subjective and much less
arbitrary than if RECs/IRBs or researchers assess whether
to allow an individual to join a particular procedure in
each case. The final argument is that of efficiency: a clearly
marked age threshold makes action and decision-making
processes easier and more straightforward.
Summary
The moral concept of personalisation of assent needs a
more practical approach in ethical guidelines and rec-
ommendations. We therefore propose modifying it with
additional suggestions about the school-age threshold.
This straightforward recommendation makes assessment
by RECs and IRBs more efficient and predictable. A
suggested age threshold minimises subjective assess-
ment regarding children’s capacity to assent and makes
the concept of assent more consistent with other social
rules. Most importantly, this clear recommendation is
more likely to be followed, and thus to serve children’s
interests better than vague and very flexible recommen-
dations of personalisation of assent.
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